Future options of anti-angiogenic cancer therapy
2016 (English)In: CHINESE JOURNAL OF CANCER, ISSN 1000-467X, Vol. 35, no 21Article, review/survey (Refereed) PublishedText
In human patients, drugs that block tumor vessel growth are widely used to treat a variety of cancer types. Many rigorous phase 3 clinical trials have demonstrated significant survival benefits; however, the addition of an anti-angiogenic component to conventional therapeutic modalities has generally produced modest survival benefits for cancer patients. Currently, it is unclear why these clinically available drugs targeting the same angiogenic pathways produce dissimilar effects in preclinical models and human patients. In this article, we discuss possible mechanisms of various anti-angiogenic drugs and the future development of optimized treatment regimens.
Place, publisher, year, edition, pages
SUN YAT SEN UNIV MED SCI WHO , 2016. Vol. 35, no 21
Angiogenesis; Cancer therapy; Anti-angiogenesis; Vascular endothelial growth factor; Biomarker
IdentifiersURN: urn:nbn:se:liu:diva-125802DOI: 10.1186/s40880-016-0084-4ISI: 000370009400002PubMedID: 26879126OAI: oai:DiVA.org:liu-125802DiVA: diva2:910327
Funding Agencies|European Research Council advanced grant ANGIOFAT ; Swedish Research Council; Swedish Cancer Foundation; Karolinska Institute Foundation; Karolinska Institute Distinguished Professor Award; Torsten Soderberg Foundation; Novo Nordisk Foundation; Knut and Alice Wallenberg Foundation2016-03-082016-03-042016-03-30